Globally, prostate cancer is the fourth most common cancer in both sexes combined and the second most common cancer in men.1 In England, prostate cancer continues to be the most common cancer diagnosed in males in 2017 with 41,201 cases diagnosed, which accounted for one in four (26.3%) male cancer diagnoses.2
We offer a wide menu of immunohistochemistry (IHC) assays. Our portfolio of products delivers the high sensitivity and specificity you need.
Our antibodies are ready-to-use on the fully automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions. We have a robust assay development program focusing on immunohistochemical staining, clinical reagents, cancer diagnostic assays and much more.